NCT04026282 (CLBR) is a NA clinical trial of GnRH-ant protocol in Sterility, sponsored by Peking University Third Hospital.

Who is sponsoring NCT04026282?

NCT04026282 is sponsored by Peking University Third Hospital.

What drugs are being tested in NCT04026282?

Interventions in NCT04026282: GnRH-ant protocol, GnRH-a long protocol.

Is NCT04026282 still recruiting?

NCT04026282 is currently status unknown. Last updated 8 November 2019.

Last reviewed 2019-11-08 · How we verify

NCT04026282: CLBR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

To Investigate the Cumulative Live Birth Rates Using GnRH Antagonist or Agonist Protocol for COS in ART Treatment

Status unknown NA Last updated 8 November 2019

What this trial tests

NA trial testing GnRH-ant protocol in Sterility in 888 participants. Status unknown.

Timeline

27 December 2018

Primary endpoint
30 October 2021

31 July 2022

Quick facts

Lead sponsor	Peking University Third Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	888
Start date	27 December 2018
Primary completion	30 October 2021
Estimated completion	31 July 2022
Sites	4 locations across China

Drugs / interventions tested

GnRH-ant protocol
GnRH-a long protocol

Conditions studied

Sterility — all drugs for Sterility →

Sponsor

Peking University Third Hospital

Who can join

Adults 18 to 38, female only, with Sterility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase IV, prospective, randomized controlled study to investigate the cumulative live birth rates (CLBRs) of gonadotrophin-releasing hormone (GnRH) antagonist protocol (GnRH-ant group) compared with the standard GnRH agonist long protocol (GnRH-a group) for controlled ovarian stimulation in supposed normal ovarian responders.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Peking University Third Hospital trials

Trials by the same sponsor.

NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04026282 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
Last refreshed: 8 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04026282.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing